Nvidia (NASDAQ:NVDA) is reportedly in advanced discussions to acquire AI21 Labs, an Israel-based artificial intelligence startup, in a deal potentially valued at up to $3 billion, according to a report from Calcalist.
FTAI Aviation (NASDAQ:FTAI) saw its shares rise by 8.8% in the morning session after announcing the launch of FTAI Power, a new venture aimed at repurposing its CFM56 aircraft engines into 25-megawatt power turbines.
Nukkleus (NASDAQ:NUKK) has successfully closed its acquisition of Tiltan Software Engineering, making the Israeli defense technology firm a wholly owned subsidiary.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced positive findings from its Phase 1b clinical study GLP-1-H24-4, a 12-week chronic trial focusing on its DehydraTECH™ (DHT) delivery platform in comparison to the Rybelsus® control arm.
Binance has confirmed the suspension of Visa and Mastercard withdrawals for users in Ukraine following changes linked to its fiat payment provider.
Cycurion closed 2025 with a strong financial position, reporting an $80 million contracted backlog and bolstered liquidity as the company accelerates into 2026.
For the third quarter of 2025, Cycurion, which trades on the Nasdaq under the ticker CYCU, reported revenue of $3.83 million, a 13.9% year-over-year decrease. However, total assets grew to $32.31 million, an increase of 26.4%, and cash reserves rose significantly to $3.65 million, compared to just $0.04 million at the end of 2024.
The company saw net financing inflows of $10.78 million and is forecasting a Q1 2026 run-rate revenue of approximately $4.17 million, which would annualize to around $16.66 million.
Recent business wins include a multi-year telecom deployment with potential revenue exceeding $1 million, a state and local government data modernization project, and a $1.1 million county contract. Cycurion also declared a pro-rata share dividend of $0.0080 per share, payable around December 30, 2025.
Cycurion’s strategic focus on government and commercial sectors continues to drive growth as the company strengthens its foundation for expansion into 2026.
Denali Therapeutics (NASDAQ:DNLI) announced promising Phase 1/2 results for tividenofusp alfa (DNL310) in the treatment of Hunter syndrome, with the data published in The New England Journal of Medicine supporting an FDA Priority Review. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for April 5, 2026.
VivoPower (NASDAQ:VVPR) announced it has entered into an exclusive heads of agreement to acquire a fully operational, >40MW data center facility in Norway, powered by 100% renewable hydropower.
Onchain perpetual contracts have surged to $972 billion in trading volume over the past 30 days, even as broader crypto market sentiment remains cautious.
Cvent, a global leader in meetings and hospitality technology, has entered into a definitive agreement to acquire ON24 (NYSE:ONTF) for approximately $400 million in an all-cash transaction.
Silo Pharma (NASDAQ:SILO) announced a non-binding Letter of Intent (LOI) with Allucent (US) LLC to support the Phase 1 clinical development of SPC-15, a nasal spray formulation under investigation.
Etoiles Capital Group (NASDAQ:EFTY) reported strong financial performance for the six months ended June 30, 2025, with a substantial 196.6% increase in revenue, reaching $1,800,576.
